Oculis Holding AG Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.

The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

The company is based in Zug, Switzerland.

Oculis Holding AG

Country	Switzerland
Industry	Biotechnology
Sector	Healthcare
Employees	36
CEO	Riad Sherif

Contact Details

Address: Bahnhofstrasse 7 Zug, 6300 Switzerland
Phone	41 41 711 9325
Website	oculis.com

Stock Details

Ticker Symbol	OCS
Exchange	Nasdaq Iceland
Fiscal Year	January - December
Reporting Currency	CHF
SIC Code	2836

Key Executives

Name	Position
Dr. Riad Sherif M.B.A., M.D.	Chief Executive Officer and Director
Sylvia Cheung	Chief Financial Officer
Gudrun Bachmann Ph.D.	Chief Technology Officer
Dr. Ramin Tadayoni M.D., Ph.D.	Chief Scientific Officer
Daniel S. Char J.D.	Chief Legal Officer
Virginia R. Dean	Chief Human Resources Officer
Páll Ragnar Jóhannesson	Chief Business Officer
Rebecca Weil	Chief Commercial Officer
Dr. Snehal Shah Pharm.D.	President of Research and Development
Dr. Sharon Klier M.D., M.P.H.	Chief Development Officer